跳至主要内容
临床试验/NL-OMON31299
NL-OMON31299招募中不适用

Influence of B cell depletion therapy (rituximab) on (risk factors of) comorbidity in rheumatoid arthritis - B cell depletion therapy in rheumatoid arthritis and comorbidity

Vrije Universiteit Medisch Centrum0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • According to the thesis of the Dutch association of rheumatology (NVR): treatment with rituximab of rheumatoid arthritis patients:
  • - rheumatoid arthritis diagnosed according to the ACR criteria 1987
  • - active rheumatoid arthritis
  • - previous failure of TNF alpha blocking

排除标准

  • - malignity
  • - active tuberculosis or other active infection
  • - pregnancy and lactation
  • - severe heart failure (NYHA IV) or other cardiac disease
  • - hypersensitivity to one of the active substances of rituximab or murine proteins

研究者

相似试验